| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802231002062 | 223100206 | VISIPAQUE INJ.SOL 550MG(270MG I)/ML BT x1 PLASTIC BOTTLE x 200 ML (P.P.) x 200 ML (P.P.) | 40.92 | 42.92 | 63.05 |
| 05/2018 | 2802231002079 | 223100207 | VISIPAQUE INJ.SOL 550MG(270MG I)/ML BT x1 PLASTIC BOTTLE x 100 ML (P.P.) x 100 ML (P.P.) | 22.45 | 23.55 | 34.60 |
| 05/2018 | 2802231002086 | 223100208 | VISIPAQUE INJ.SOL 550MG(270MG I)/ML BT x1 PLASTIC BOTTLE x 50 ML (P.P.) x 50 ML (P.P.) | 12.20 | 12.80 | 18.80 |
| 05/2018 | 2802231003069 | 223100306 | VISIPAQUE INJ.SOL 652MG(320MG I)/ML BT x1 PLASTIC BOTTLE x 200 ML (P.P.) x 200 ML (P.P.) | 49.14 | 51.55 | 69.90 |
| 05/2018 | 2802231003076 | 223100307 | VISIPAQUE INJ.SOL 652MG(320MG I)/ML BTx 1PLASTIC BOTTLE x 100 ML (P.P.) x 100 ML (P.P.) | 23.52 | 24.67 | 36.24 |
| 05/2018 | 2802231003083 | 223100308 | VISIPAQUE INJ.SOL 652MG(320MG I)/ML BTx 1PLASTIC BOTTLE x 50 ML (P.P.) x 50 ML (P.P.) | 11.33 | 11.89 | 17.47 |
Used as a contrast agent during coronary angiography.
Organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur.
2.1 hours. In patients with significantly impaired renal function (mean creatinine clearance rate, 9.91 [± 3.58] mL per minute), the plasma half-life is increased to 23 hours.
In adults, approximately 97% of the injected dose of iodixanol is excreted unchanged in urine within 24 hours, with less than 2% excreted in feces within five days post-injection.
* 0.26 L/kg